PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $84,864,191 | +19.8% | 2,449,183 | 0.0% | 21.18% | +1218.9% |
| Q1 2024 | $70,854,864 | +26.2% | 2,449,183 | 0.0% | 1.61% | +25.5% |
| Q4 2023 | $56,159,766 | +37.5% | 2,449,183 | 0.0% | 1.28% | -91.5% |
| Q3 2023 | $40,852,372 | -39.6% | 2,449,183 | 0.0% | 15.05% | -28.4% |
| Q2 2023 | $67,646,434 | +20.1% | 2,449,183 | 0.0% | 21.00% | +14.6% |
| Q1 2023 | $56,331,209 | +210712.5% | 2,449,183 | 0.0% | 18.32% | +135.7% |
| Q4 2022 | $26,721 | -99.9% | 2,449,183 | 0.0% | 7.77% | +27.9% |
| Q3 2022 | $20,647,000 | +6.6% | 2,449,183 | 0.0% | 6.08% | +22.8% |
| Q2 2022 | $19,373,000 | -66.6% | 2,449,183 | 0.0% | 4.95% | -54.9% |
| Q1 2022 | $57,997,000 | -30.8% | 2,449,183 | 0.0% | 10.96% | +15.0% |
| Q4 2021 | $83,762,000 | +93.0% | 2,449,183 | 0.0% | 9.54% | +150.5% |
| Q3 2021 | $43,400,000 | – | 2,449,183 | – | 3.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $84,864,191 | 21.18% |
| Cannon Global Investment Management, LLC | 69,900 | $2,422,035 | 11.28% |
| ADAR1 Capital Management, LLC | 1,603,932 | $55,576,244 | 10.49% |
| Checkpoint Capital L.P. | 355,000 | $12,300,750 | 7.42% |
| Fairmount Funds Management LLC | 931,890 | $32,289,989 | 3.65% |
| BVF INC/IL | 3,319,290 | $115,013,399 | 3.22% |
| RTW INVESTMENTS, LP | 5,286,404 | $183,173,899 | 2.84% |
| Kynam Capital Management, LP | 800,000 | $27,720,000 | 2.14% |
| 683 Capital Management, LLC | 604,449 | $20,944,158 | 1.58% |
| Birchview Capital, LP | 48,000 | $1,663,200 | 1.54% |